MedTrace Logo

Tanezumab and Nerve Function In Arthritis Patients

NCT00863772 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2021-02-04

Study results available
· View outcomes & findings →

Summary

Tanezumab reduces pain of osteoarthritis without affecting how nerve impulses are transmitted in sensory nerves.

Conditions

Interventions

BIOLOGICAL

tanezumab

5 mg dose Intravenously every 8 weeks for duration of study

BIOLOGICAL

tanezumab

10 mg dose Intravenously every 8 weeks for duration of study

OTHER

Placebo

Placebo, Intravenously, every 8 weeks for duration of study

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-18
Primary Completion
2010-11-16
Completion
2010-11-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00863772 on ClinicalTrials.gov